Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2008 Oct 18;22(16):2143-53.
doi: 10.1097/QAD.0b013e3283112b77.

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

Antonella d'Arminio Monforte  1 , Donald Abrams, Christian Pradier, Rainer Weber, Peter Reiss, Fabrice Bonnet, Ole Kirk, Matthew Law, Stephane De Wit, Nina Friis-Møller, Andrew N Phillips, Caroline A Sabin, Jens D Lundgren; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group
Collaborators, Affiliations
Multicenter Study

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

Antonella d'Arminio Monforte et al. AIDS. .

Abstract

Objective: To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency.

Design: Observational cohort study.

Methods: Patients (23 437) were followed prospectively for 104 921 person-years. We used Poisson regression models to identify factors independently associated with deaths from ADM and nADM. Analyses of factors associated with mortality due to nADM were repeated after excluding nADM known to be associated with a specific risk factor.

Results: Three hundred five patients died due to a malignancy, 298 prior to the cutoff for this analysis (ADM: n = 110; nADM: n = 188). The mortality rate due to ADM decreased from 20.1/1000 person-years of follow-up [95% confidence interval (CI) 14.4, 25.9] when the most recent CD4 cell count was <50 cells/microl to 0.1 (0.03, 0.3)/1000 person-years of follow-up when the CD4 cell count was more than 500 cells/microl; the mortality rate from nADM decreased from 6.0 (95% CI 3.3, 10.1) to 0.6 (0.4, 0.8) per 1000 person-years of follow-up between these two CD4 cell count strata. In multivariable regression analyses, a two-fold higher latest CD4 cell count was associated with a halving of the risk of ADM mortality. Other predictors of an increased risk of ADM mortality were homosexual risk group, older age, a previous (non-malignancy) AIDS diagnosis and earlier calendar years. Predictors of an increased risk of nADM mortality included lower CD4 cell count, older age, current/ex-smoking status, longer cumulative exposure to combination antiretroviral therapy, active hepatitis B infection and earlier calendar year.

Conclusion: The severity of immunosuppression is predictive of death from both ADM and nADM in HIV-infected populations.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Rates of mortality from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) (with 95% CI) stratified by (a) latest CD4 cell count and (b) latest HIV RNA. ADM, AIDS-defining malignancies; PYFU, personyears of follow-up.
See this image and copyright information in PMC

References

    1. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. for the EuroSIDA study group Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002;16:1663–1671. - PubMed
    1. Lewden C, Salmon D, Morlat P, Jougla E, Bonnet F, Hériprete L, et al. Causes of death among human immunodeficiency viruses (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34:121–130. - PubMed
    1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. HIV Outpatient Study Investigators Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860. - PubMed
    1. Salmon-Ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799–805. - PubMed
    1. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423–1430. - PubMed

Publication types

MeSH terms

Substances